Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Jul 1, 2015 Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
Jun 29, 2015 Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of RINTEGA(R) (rindopepimut) in Newly Diagnosed Glioblastoma
What's New

2012 Form 10-K

More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Apr 29, 2015 Form 10-Q View HTML View PDF 312.8 KB Add to Briefcase
Feb 24, 2015 Form 10-K View HTML View PDF 1.1 MB Add to Briefcase
Add to Briefcase = add file to Briefcase